Alcon announced the completion of the acquisition of Ivantis, according to a press release. Ivantis is the developer of the Hydrus Microstent, a minimally invasive glaucoma surgery device designed to lower eye pressure for patients with open-angle glaucoma in connection with cataract surgery.
“We believe this transaction will further strengthen our global surgical portfolio and help provide a platform for more growth in the glaucoma space,” said David Endicott, CEO of Alcon. “As we welcome Ivantis associates into Alcon, we look forward to introducing Hydrus Microstent on a broader, global scale in the near future to help even more patients see brilliantly.”
Read the full press release here.
Related Content
